Jason B Fleming

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint MicroRNA dissects out dangerous pancreatic cysts from all the rest
    Ryan M Thomas
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 18:4482-4. 2012
  2. doi request reprint Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma
    Jason B Fleming
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    Arch Surg 144:216-21. 2009
  3. ncbi request reprint Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution
    Jeannelyn S Estrella
    Departments of Pathology Gastrointestinal Medical Oncology Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Gastroenterology, Changhai Hospital, The Second Military Medical University, Shanghai, China
    Am J Surg Pathol 38:147-57. 2014
  4. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
  5. pmc Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma
    Deyali Chatterjee
    Departments of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 36:409-17. 2012
  6. doi request reprint Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
  7. ncbi request reprint Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT
    Wei Wang
    Department of Gastroenterology, Hepatology, and Nutrition, MD Anderson Cancer Center, Houston, TX 77030, USA
    Gastrointest Endosc 78:73-80. 2013
  8. doi request reprint Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Surg Oncol 18:3615-22. 2011
  9. pmc Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 14:365-72. 2012
  10. pmc Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy
    Deyali Chatterjee
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 36:552-9. 2012

Research Grants

Collaborators

Detail Information

Publications83

  1. ncbi request reprint MicroRNA dissects out dangerous pancreatic cysts from all the rest
    Ryan M Thomas
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 18:4482-4. 2012
    ..The diagnostic dilemma is identifying which cysts pose a cancerous threat. Cyst fluid has been analyzed in a variety of ways to answer this question but the microRNA (miRNA) profile of the fluid may finally hold the answer...
  2. doi request reprint Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma
    Jason B Fleming
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1400 Holcombe Blvd, Unit 444, Houston, TX 77030, USA
    Arch Surg 144:216-21. 2009
    ..To examine the influence of obesity, as measured by body mass index (BMI) (calculated as weight in kilograms divided by height in meters squared), on clinicopathologic factors and survival after pancreatectomy to treat adenocarcinoma...
  3. ncbi request reprint Solid pseudopapillary neoplasm of the pancreas: clinicopathologic and survival analyses of 64 cases from a single institution
    Jeannelyn S Estrella
    Departments of Pathology Gastrointestinal Medical Oncology Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Department of Gastroenterology, Changhai Hospital, The Second Military Medical University, Shanghai, China
    Am J Surg Pathol 38:147-57. 2014
    ..001) were important predictors of disease-specific survival in patients with SPN. Our study highlights the importance of pathologic evaluation in risk assessment in patients with SPNs. ..
  4. doi request reprint Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:2045-53. 2012
    ..By means of this system, we sought to analyze outcomes of patients with resectable anatomy but heterogeneous biology and physiology who were treated with neoadjuvant therapy...
  5. pmc Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma
    Deyali Chatterjee
    Departments of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 36:409-17. 2012
    ..Our results showed that PNI plays an important role in the progression of PDAC and in predicting prognosis in this group of patients...
  6. doi request reprint Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, USA
    J Gastrointest Surg 16:68-78; discussion 78-9. 2012
    ..To determine the influence of neoadjuvant chemoradiation and standardized dissection of the superior mesenteric artery upon the oncologic outcome of patients with localized pancreatic adenocarcinoma...
  7. ncbi request reprint Use of EUS-FNA in diagnosing pancreatic neoplasm without a definitive mass on CT
    Wei Wang
    Department of Gastroenterology, Hepatology, and Nutrition, MD Anderson Cancer Center, Houston, TX 77030, USA
    Gastrointest Endosc 78:73-80. 2013
    ..Diagnosis of pancreatic neoplasm is challenging in patients with inconclusive findings on pancreatic multidetector row CT (MDCT)...
  8. doi request reprint Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Ann Surg Oncol 18:3615-22. 2011
    ..We conducted a phase II trial to assess the survival duration and quality of life of patients who received adjuvant interferon-based chemoradiation for pancreatic adenocarcinoma after pancreaticoduodenectomy...
  9. pmc Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    HPB (Oxford) 14:365-72. 2012
    ..Following potentially curative resection at this centre, patients with pancreatic adenocarcinoma (PAC) are routinely enrolled in a programme of clinical and radiographic surveillance. This study sought to evaluate its diagnostic yield...
  10. pmc Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy
    Deyali Chatterjee
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 36:552-9. 2012
    ..Our results showed that tumor invasion into muscular vessels plays an important role in the progression of PDAC and in predicting prognosis in this group of patients...
  11. ncbi request reprint Clinicopathologic features and prognosis of duodenal adenocarcinoma and comparison with ampullary and pancreatic ductal adenocarcinoma
    Maryam Zenali
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
    Hum Pathol 44:2792-8. 2013
    ..Patients with DAC had less frequent nodal metastasis and better prognosis than those with PDA. There was no significant difference in prognosis between DAC and AA. ..
  12. pmc Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation
    Jiansheng Wang
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 118:3801-11. 2012
    ..However, the prognostic significance of tumor involvement of the resected vein in patients who received neoadjuvant therapy is unclear...
  13. pmc Deciphering the mechanisms of tumorigenesis in human pancreatic ductal epithelial cells
    Zhe Chang
    Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Clin Cancer Res 19:549-59. 2013
    ..In this study, we investigated the mechanism of tumorigenic transformation in the immortalized human pancreatic ductal epithelial (HPDE) cell line by sequentially introducing PDAC signature alterations into this cell line...
  14. doi request reprint A high positive lymph node ratio is associated with distant recurrence after surgical resection of ampullary carcinoma
    Christina L Roland
    Division of Surgery, Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Gastrointest Surg 16:2056-63. 2012
    ..However, the use of the LNR to predict distant recurrence risk remains unknown. The purpose of this study was to determine if the LNR is associated with distant recurrence risk...
  15. pmc Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection
    Ryan M Thomas
    Department of Surgical Oncology, Unit 444, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Gastrointest Surg 16:1696-704. 2012
    ..Resection of certain recurrent malignancies can prolong survival, but resection of recurrent pancreatic ductal adenocarcinoma is typically contraindicated because of poor outcomes...
  16. pmc Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome
    Deyali Chatterjee
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:3182-90. 2012
    ..Several grading schemes for the extent of residual tumor in posttreatment pancreaticoduodenectomy (PD) specimens have been proposed. However, the prognostic significance of these grading schemes is unknown...
  17. doi request reprint Post-therapy pathologic stage and survival in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemoradiation
    Jeannelyn S Estrella
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:268-77. 2012
    ..However, analysis of prognostic factors is limited for patients with PDAC treated with neoadjuvant chemoradiation and pancreaticoduodenectomy (PD)...
  18. pmc Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 16:836-47. 2009
    ..We evaluated long-term survival and patterns of recurrence in patients treated for PC with contemporary staging and multimodality therapy...
  19. ncbi request reprint Aberrant expression of p53, p21, cyclin D1, and Bcl2 and their clinicopathological correlation in ampullary adenocarcinoma
    Rongjun Guo
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030
    Hum Pathol 45:1015-23. 2014
    ..Our study showed that p53, p21, and cyclin D1, but not Bcl2, are frequently overexpressed in AAs. Cyclin D1 overexpression is associated with increased risk of disease recurrence and worse survival in patients with AA after resection. ..
  20. doi request reprint Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:2197-203. 2013
    ..Few data exist to guide oncologic surveillance following curative treatment of pancreatic cancer. We sought to identify a rational, cost-effective postoperative surveillance strategy...
  21. doi request reprint Fear of cancer recurrence after curative pancreatectomy: a cross-sectional study in survivors of pancreatic and periampullary tumors
    Maria Q B Petzel
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:4078-84. 2012
    ....
  22. pmc Risk of venous thromboembolism outweighs post-hepatectomy bleeding complications: analysis of 5651 National Surgical Quality Improvement Program patients
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    HPB (Oxford) 14:506-13. 2012
    ..The relationships between extent of hepatectomy, postoperative VTE and bleeding events were evaluated using the National Surgical Quality Improvement Program (NSQIP) database...
  23. pmc Loss of phosphatase and tensin homolog expression is associated with recurrence and poor prognosis in patients with pancreatic ductal adenocarcinoma
    Wai Chin Foo
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Hum Pathol 44:1024-30. 2013
    ..05). Assessment of PTEN expression may be used as a prognostic marker for patients with resected pancreatic ductal adenocarcinoma...
  24. pmc Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma
    Shaofan Weng
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Epidemiol Biomarkers Prev 21:1336-43. 2012
    ..Using univariate and multivariate analysis, we correlated PP4C expression with survival and other clinicopathologic features...
  25. ncbi request reprint Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy
    Michael P Kim
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 19:S395-403. 2012
    ..We sought to identify consistent, differentially expressed genes between treatment of naive pancreatic tumors and those exposed to neoadjuvant therapy using a strict, in vivo direct xenograft model system...
  26. doi request reprint Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:5749-56. 2012
    ..In this study, the authors sought to determine the rate at which neoadjuvant therapy is associated with a reduction in the size or stage of borderline resectable tumors...
  27. doi request reprint Diagnosis and management of cystic neoplasms of the pancreas: an evidence-based approach
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 207:106-20. 2008
  28. pmc Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration
    Mark J Truty
    Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 215:41-51; discussion 51-2. 2012
    ..We hypothesized that accurate radiographic restaging, multimodality treatment, and advanced surgical technique can offer patients deemed unresectable at previous exploration the possibility for curative salvage pancreatectomy...
  29. pmc Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230, USA
    Arch Surg 147:513-9. 2012
    ..To calculate conditional survival estimates for patients with pancreatic adenocarcinoma...
  30. pmc Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis
    Qing Zhao
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Ann Diagn Pathol 16:29-37. 2012
    ..Patients with pCR had a better survival than did those who had posttherapy stage I or IIA disease (P < .001). Patients with PDA who received neoadjuvant therapy and had pCR in pancreatectomy are rare but have a better prognosis...
  31. pmc TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation
    Zhongkui Li
    Departments of Surgical Oncology and Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 69:7851-9. 2009
    ..Therefore, our results showed that TrkBT1 overexpression induces liver metastasis of pancreatic cancer and uncovered a unique signaling mechanism by which TrkBT1 sequesters GDI and activates RhoA signaling...
  32. doi request reprint Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma
    Xianzhou Song
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:734-43. 2011
    ..Although previous studies have identified the role of Axl in the transformation, proliferation, survival, and invasion in cancers, the expression and functions of Axl in pancreatic cancer have not been studied in detail...
  33. pmc Resection of at-risk mesenteric lymph nodes is associated with improved survival in patients with small bowel neuroendocrine tumors
    Christine S Landry
    Department of Surgical Oncology, Baylor University Medical Center, 3410 Worth Street, Suite 235, Dallas, TX 75246, USA
    World J Surg 37:1695-700. 2013
    ..We hypothesized that the extent of lymphadenectomy reported in a large administrative database would be associated with overall survival for jejunal and ileal neuroendocrine tumors...
  34. pmc Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma
    Deyali Chatterjee
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Histopathology 63:841-51. 2013
    ..To study the histological changes in non-neoplastic pancreas and the effects on pancreatic intraepithelial neoplasia (PanIN) after neoadjuvant chemoradiation therapy (NCRT) for pancreatic ductal adenocarcinoma (PDAC)...
  35. doi request reprint Pancreatic neuroendocrine neoplasms: diagnosis and management
    Aparna Balachandran
    Department of Diagnostic Radiology, University of Texas MD Anderson Cancer Center, Unit 1473, P O Box 301402, Houston, TX 77030, USA
    Abdom Imaging 38:342-57. 2013
    ..There is an increased role for both anatomic and functional imaging in the assessment of these neoplasms. A review of the nomenclature, staging, and imaging is presented in this paper...
  36. doi request reprint Imaging of pancreatic adenocarcinoma: update on staging/resectability
    Eric P Tamm
    Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1473, Houston, TX 77030, USA
    Radiol Clin North Am 50:407-28. 2012
    ..Clear and concise reporting of imaging findings is important. Several national organizations are developing templates to standardize the reporting of imaging findings...
  37. doi request reprint Endoscopic management of duodenal adenomas in familial adenomatous polyposis--a single-center experience
    Sathya Jaganmohan
    Department of Gastroenterology, MD Anderson Cancer Center, Houston, TX, USA
    Dig Dis Sci 57:732-7. 2012
    ..Duodenal lesions (DLS) are common in patients with familial adenomatosis polyposis (FAP), and screening for duodenal adenocarcinoma (DA) is currently recommended. Endoscopic treatment of DLS is controversial...
  38. ncbi request reprint Multidisciplinary management strategy for incidental cystic lesions of the pancreas
    Debashish Bose
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Am Coll Surg 211:205-15. 2010
    ..Management of these patients is unclear because a small but significant number of incidental pancreatic cysts are malignant...
  39. doi request reprint Borderline resectable pancreatic cancer: the importance of this emerging stage of disease
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Am Coll Surg 206:833-46; discussion 846-8. 2008
    ..There is no optimal treatment schema for this distinct stage of disease, so the role of surgery is undefined...
  40. ncbi request reprint Race does not impact pancreatic cancer treatment and survival in an equal access federal health care system
    Sukhyung Lee
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg Oncol 20:4073-9. 2013
    ..We sought to determine whether disparities in clinical management and overall survival exist between black and white patients with PDAC treated in an equal access health care system...
  41. pmc SOX9: a useful marker for pancreatic ductal lineage of pancreatic neoplasms
    Stuti Shroff
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX77030, USA
    Hum Pathol 45:456-63. 2014
    ..Our study showed that SOX9 is expressed in centroacinar and ductal epithelial cells of BP and is a useful marker for pancreatic ductal lineage of pancreatic neoplasms. ..
  42. pmc Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
    Ching Wei D Tzeng
    Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    HPB (Oxford) 16:430-8. 2014
    ..The purpose of this study was to determine the relationship between carbohydrate antigen (CA) 19-9 levels and outcome in patients with borderline resectable pancreatic cancer treated with neoadjuvant therapy (NT)...
  43. ncbi request reprint Morbidity and mortality after pancreaticoduodenectomy in patients with borderline resectable type C clinical classification
    Ching Wei D Tzeng
    Department of Surgical Oncology, Unit 1484, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA
    J Gastrointest Surg 18:146-55; discussion 155-6. 2014
    ..This study was designed to analyze the incidence and risk factors for post-pancreaticoduodenectomy (PD) morbidity/mortality in a multi-institutional cohort of BR-C patients...
  44. doi request reprint High levels of nucleolar expression of nucleolin are associated with better prognosis in patients with stage II pancreatic ductal adenocarcinoma
    Lan Peng
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:3734-42. 2010
    ..However, the expression and significance of nucleolin in pancreatic ductal adenocarcinoma (PDA) have not been studied...
  45. pmc Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression
    Christopher H Crane
    Dept of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX
    J Clin Oncol 29:3037-43. 2011
    ..This phase II trial was designed to assess the efficacy and safety of cetuximab, gemcitabine, and oxaliplatin followed by cetuximab, capecitabine, and radiation therapy in locally advanced pancreatic cancer (LAPC)...
  46. doi request reprint Retroperitoneal dissection in patients with borderline resectable pancreatic cancer: operative principles and techniques
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 215:e11-8. 2012
    ..The technical approaches we have described here can be used as a basic foundation for operative safety and efficiency during these challenging operations...
  47. pmc KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma
    Jianhua Ling
    Department of Molecular and Cellular Oncology, The University of Texas M D Anderson Cancer Centre, Houston, 77030, USA
    Cancer Cell 21:105-20. 2012
    ..Therefore, our findings demonstrate the mechanism by which IKK2/β/NF-κB is activated by Kras(G12D) through dual feedforward loops of IL-1α/p62...
  48. pmc ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma
    Michael P Kim
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e20636. 2011
    ..Understanding which pancreatic cancer cell populations possess tumor-initiating capabilities is critical to characterizing and understanding the biology of pancreatic CSCs towards therapeutic ends...
  49. pmc Current status of adjuvant therapy for pancreatic cancer
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 15:1205-13. 2010
    ..Well-designed prospective trials are needed to define the optimal adjuvant or neoadjuvant therapy strategy for these patients...
  50. pmc Solid pseudopapillary neoplasm of the pancreas with prominent atypical multinucleated giant tumour cells
    Lei Li
    Department of Pathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Histopathology 62:465-71. 2013
    ..Solid pseudopapillary neoplasm of the pancreas (SPN) is a rare low-grade malignant neoplasm. To our knowledge, SPN with prominent atypical multinucleated giant tumour cells (MNGTCs) has not yet been reported...
  51. doi request reprint Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors
    Aparna Balachandran
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    AJR Am J Roentgenol 199:602-8. 2012
    ..We sought to determine the incidence of venous tumor thrombus in nonfunctioning pancreatic neuroendocrine tumors...
  52. doi request reprint Tumor-node-metastasis staging of pancreatic adenocarcinoma
    Matthew H G Katz
    Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 58:111-25. 2008
    ....
  53. ncbi request reprint Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer
    Amanda B Cooper
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
    J Am Coll Surg 219:111-20. 2014
    ..We sought to describe the treatment patterns and outcomes of a series of elderly patients with pancreatic cancer who were treated with a multimodality strategy that liberally used neoadjuvant therapy...
  54. pmc Predicting the risks of venous thromboembolism versus post-pancreatectomy haemorrhage: analysis of 13,771 NSQIP patients
    Ching Wei D Tzeng
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    HPB (Oxford) 16:373-83. 2014
    ..The secondary hypothesis was that patients at high risk for post-discharge VTE could be identified, potentially facilitating the selective use of extended chemoprophylaxis...
  55. pmc Radiographic tumor-vein interface as a predictor of intraoperative, pathologic, and oncologic outcomes in resectable and borderline resectable pancreatic cancer
    Hop S Tran Cao
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1400 Pressler Street, FCT 17 6058, Houston, TX, 77230 1402, USA
    J Gastrointest Surg 18:269-78; discussion 278. 2014
    ..We assessed the ability of radiographic criteria to predict the need for superior mesenteric-portal vein (SMV-PV) resection and the presence of histologic vein invasion...
  56. pmc LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
    Davide Melisi
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Mol Cancer Ther 7:829-40. 2008
    ..Targeting TbetaRI/II kinase activity on pancreatic cancer cells or the cells of the liver microenvironment represents a novel therapeutic approach to prevent pancreatic cancer metastasis...
  57. doi request reprint Metastatic adult granulosa cell tumor mimicking a benign pancreatic cyst
    Rania A Abadeer
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Diagn Pathol 14:457-60. 2010
    ..Immunohistochemical study and clinical history were critical to make the correct diagnosis and to differentiate this tumor from other more commonly encountered cystic neoplasms of the pancreas...
  58. ncbi request reprint Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy
    Matthew H G Katz
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Ann Surg 248:1098-102. 2008
    ..To describe our approach to resection of pancreatic head cancers, which involve 1 or both of the first-order branches of the superior mesenteric vein (SMV)...
  59. doi request reprint Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice
    Michael P Kim
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Nat Protoc 4:1670-80. 2009
    ..Once established, direct xenograft tumors require 2 and 5 h for heterotopic and orthotopic implantation, respectively, and 5-6 weeks for palpable tumor growth...
  60. ncbi request reprint Feasibility study of EUS-NOTES as a novel approach for pancreatic cancer staging and therapy: an international collaborative study
    Adrian Saftoiu
    Department of Gastroenterology, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Hepatogastroenterology 60:180-6. 2013
    ..The aim of the study was to assess the EUS-guided diagnostic and therapeutic procedures during NOTES for both anterior and posterior approach of the pancreas...
  61. doi request reprint Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases
    Ashwani K Singal
    Department of Gastroenterology Hepatology and Nutrition, Unit 1466, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Dig Dis Sci 56:3678-84. 2011
    ..To study pre-operative and peri-operative course and outcome on follow up after pancreaticoduodenenctomy (PD) for resectable pancreatic cancer amongst patients receiving self-expanding metal stents (SEMS)...
  62. doi request reprint Role of EUS-FNA-based cytology in the diagnosis of mucinous pancreatic cystic lesions: a systematic review and meta-analysis
    Nirav Thosani
    Department of Internal Medicine, The University of Texas Health Sciences Center at Houston, Houston, TX, USA
    Dig Dis Sci 55:2756-66. 2010
    ..Preoperative diagnosis of malignancy in pancreatic cystic lesions (PCLs) remains challenging. Most non-mucinous cystic lesions (NMCLs) are benign, but mucinous cystic lesions (MCLs) are more likely to be premalignant or malignant...
  63. doi request reprint Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer
    Rosa F Hwang
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Ann Surg Oncol 15:1356-66. 2008
    ..We describe the development of an integrated pancreatic tissue bank (PTB) and clinical database for patients with pancreatic cancer and other pancreatic disorders...
  64. ncbi request reprint Current diagnosis and management of unusual pancreatic tumors
    Melinda M Mortenson
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg 196:100-13. 2008
    ....
  65. pmc Study human pancreatic cancer in mice: how close are they?
    Yuqing Zhang
    Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, USA
    Biochim Biophys Acta 1835:110-8. 2013
    ..This information is critical for the development of new methods to screen, treat, and prevent pancreatic cancer...
  66. doi request reprint Combined esophagectomy and pancreaticoduodenectomy: expanded indication for supercharged jejunal interposition
    Jae Yul Kim
    Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Gastrointest Surg 15:1893-5. 2011
    ..Combined pancreaticoduodenectomy and esophagectomy poses a challenge for reconstruction...
  67. doi request reprint Serum brain naturietic peptide measurements reflect fluid balance after pancreatectomy
    Richard N Berri
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4008, USA
    J Am Coll Surg 214:778-87. 2012
    ..We hypothesized that sequential measurement of currently available serum proteins will indicate fluid balance...
  68. doi request reprint The recognition and surgical management of heritable lesions of the pancreas
    Michael P Kim
    Department of Surgical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Surg Oncol Clin N Am 18:99-119, ix. 2009
    ....
  69. ncbi request reprint K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways
    Yoichi Matsuo
    Department of Gastroenterology, The University of Texas M D Anderson Cancer Center, Houston, USA
    Mol Cancer Res 7:799-808. 2009
    ....
  70. ncbi request reprint Distal pancreatectomy for isolated metastasis of endometrial carcinoma to the pancreas
    Dan G Blazer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1402, USA
    JOP 9:56-60. 2008
    ..Herein, we report what to our knowledge is the first description of pancreatic resection of metastatic endometrial carcinoma...
  71. doi request reprint The fallen one: the inferior parathyroid gland that descends into the mediastinum
    Glenda G Callender
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Am Coll Surg 208:887-93; discussion 893-5. 2009
    ..Our nomenclature system designates these glands as "fallen" (type F) glands. This study reviews our experience with type F parathyroid glands to determine which can be retrieved successfully through a cervical incision...
  72. pmc Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors
    Puja Gaur
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77230 1402, USA
    Gastroenterology 141:1728-37. 2011
    ..We sought to identify gastrointestinal neuroendocrine CSCs (N-CSCs) in surgical specimens and a NET cell line and to characterize novel N-CSC therapeutic targets...
  73. pmc Defective feedback regulation of NF-kappaB underlies Sjogren's syndrome in mice with mutated kappaB enhancers of the IkappaBalpha promoter
    Bailu Peng
    Departments of Surgical Oncology Research, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 107:15193-8. 2010
    ....
  74. ncbi request reprint Suppression of tumorigenesis and induction of p15(ink4b) by Smad4/DPC4 in human pancreatic cancer cells
    Bailu Peng
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 8:3628-38. 2002
    ..We seek to determine the role of Smad4/DPC4 in the suppression of tumor cell growth and in the regulation of TGF-beta-mediated expression of cell-cycle regulatory genes p15(ink4b) and p21(waf1)...
  75. ncbi request reprint One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
    James C Yao
    Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    J Clin Oncol 26:3063-72. 2008
    ..Clinicians need to be become familiar with the natural history and patterns of disease progression, which are characteristic of these tumors...
  76. ncbi request reprint Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice
    Adam W Beck
    Simmons Comprehensive Cancer Center and Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    Int J Cancer 118:2639-43. 2006
    ..In conclusion, 3G4 enhanced the anti-tumor and anti-metastatic activity of gemcitabine without contributing to toxicity...
  77. ncbi request reprint Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy
    Jason B Fleming
    Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390 8593, USA
    Mol Cancer Res 3:413-23. 2005
    ..We have found that silencing mutant K-ras through RNAi results in alteration of tumor cell behavior in vitro and suggests that targeting mutant K-ras specifically might be effective against pancreatic cancer in vivo...
  78. doi request reprint Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice
    Sean P Dineen
    Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    Cancer Res 68:4340-6. 2008
    ..Our results show an underappreciated mechanism of action that may directly contribute to the antitumor activity of angiogenesis inhibitors that block the VEGFR2 pathway...
  79. ncbi request reprint Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts
    Shane E Holloway
    Department of Surgery, Division of Surgical Oncology, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, Texas 75390 8593, USA
    Ann Surg Oncol 13:1145-55. 2006
    ..In this study, we evaluated the efficacy of 2C3, an antibody that inhibits VEGF receptor 2 activation by human VEGF, to inhibit the growth of human pancreatic adenocarcinoma in mice...
  80. ncbi request reprint Increased expression of Cyr61 (CCN1) identified in peritoneal metastases from human pancreatic cancer
    Shane E Holloway
    Division of Surgical Oncology, Department of Surgery, Hamon Center for Therapeutic Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390 8593, USA
    J Am Coll Surg 200:371-7. 2005
    ..We hypothesized that comparison of ECM-associated gene expression in primary and metastatic pancreatic tumors would identify ECM proteins associated with pancreatic metastasis...
  81. ncbi request reprint Functional imaging of angiogenesis in an orthotopic model of pancreatic cancer
    Jason B Fleming
    The Hamon Center for Therapeutic Oncology Research and the Department of Surgery, University of Texas, Southwestern Medical Center, Dallas, Texas 75390 8593, USA
    J Cell Biochem 90:492-501. 2003
    ..In this review, we will use the example of orthotopic mouse models of pancreatic cancer as a tool to survey the challenges and possibilities of functional imaging of angiogenesis, a critical determinant of metastasis...
  82. ncbi request reprint Inactivation of tumor suppressor genes by promoter methylation is important in the pathogenesis of pancreatic cancer
    Jason B Fleming
    Department of Surgery, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, 6000 Harry Hines Blvd, Dallas, TX 75390 8593, USA
    Cancer Biol Ther 1:297-9. 2002
  83. ncbi request reprint Superficial femoral vein as a conduit for portal vein reconstruction during pancreaticoduodenectomy
    Jason B Fleming
    Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
    Arch Surg 140:698-701. 2005

Research Grants1

  1. VEGF Promotes Pancreatic Tumor Cell Arrest in the Liver
    Jason Fleming; Fiscal Year: 2005
    ..abstract_text> ..